Oral Session

Oral Session 3-12B MM: Drug responses

Sun. Oct 14, 2018 9:40 AM - 10:40 AM No.12 (Osaka International Convention Center, 10F 1006-7)

Chair: Naoya Mimura (Department of Transfusion Medicine and Cell Therapy Chiba University Hospital, Japan)

+Add all to schedule

[OS3-12B-1] CD38 expression and CD38⁺ Tregs affect the response of multiple myeloma patients to daratumumab

Akihiro Kitadate, Hiroki Kobayashi, Yoshiaki Abe, Kentaro Narita, Masami Takeuchi, Kosei Matsue (Department of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan)

[OS3-12B-2] Expression levels of CRBN, IKZF1, and IKZF3 at pre- and post- lenalidomide treatment

Shiori Kinoshita, Masaki Ri, Takashi Kanamori, Sho Aoki, Takashi Yoshida, Tomoko Narita, Haruhito Totani, Asahi Ito, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida (Hematol and Oncol., Nagoya City Univ.,Nagoya, Japan)

[OS3-12B-3] ABCB1 polymorphism influence the pharmacokinetics of lenalidomide in patients with multiple myeloma

Takahiro Kobayashi¹, Maiko Abumiya², Yumiko Akamine², Fumiko Ito¹, Seiji Shida¹, Masatomo Miura², Naoto Takahashi¹ (1.Hematol., Akita Univ., Akita, Japan, 2.Pharmacy., Akita Univ Hosp., Akita, Japan)

[OS3-12B-4] Proteasome inhibitors work as immunomodulatory drugs by inducing immunogenic cell death

Sho Kashiwazaki, Satoshi Kamiko, Ryo Uozaki, Tomofumi Yamamoto, Daiju Ichikawa, Yutaka Hattori, Maiko Matsushita (Keio Univ., Tokyo, Japan)

[OS3-12B-5] Not all patients with CCND1-positive multiple myeloma show favorable outcome even with novel agents

Takuto Tachita¹, Tomoko Narita¹, Masaki Ri¹, Takayuki Murase², Sho Aoki¹, Shiori Kinoshita¹, Yoshiko Ohshima¹, Haruna Fujinami¹, Takashi Kanamori¹, Haruhito Totani¹, Ayako Masaki², Asahi Ito¹, Shigeru Kusumoto¹, Hirokazu Komatsu¹, Hiroshi Inagaki¹, Shinsuke Iida¹ (1.Hematology and Oncology, Nagoya City University,Nagoya,Japan, 2.Pathology and Molecular Diagnostics, Nagoya City University,Nagoya,Japan)

[OS3-12B-6] Detailed bone marrow plasma cell phenotyping in the patients with suspected plasma cell disorders

Satoshi Yoshihara^1,2, Kyoko Yoshihara¹, Junko Ikemoto², Hitomi Onomoto², Hiroki Sugiyama², Kazuhiro Ikegame¹, Hiroya Tamaki¹, Masaya Okada¹, Yuko Osugi¹, Yoshihiro Fujimori^1,2 (1.Hematology, Hyogo College of Medicine, Hyogo, Japan, 2.Transfusion Medicine/Cellular Therapy, Hyogo College of Medicine, Hyogo, Japan)